More Neurizon Therapeutics Limited news
Neurizon Therapeutics LimitedASX: NUZ

PharmAust receives ethics approval for Phase I trial in MND

Jun 1, 2021 at 10:44 PM EDT · Issued by Neurizon Therapeutics Limited

Filed with ASX · Jun 1, 2021 at 10:44 PM EDT · 3 pages · English

On 6ix: 6ix.com/news/pharmaust-receives-ethics-approval-for-phase-i-trial-in-mnd

Neurizon Therapeutics Limited on 6ix

Story so far

  • PharmAust Receives Pre-Approval for R&D Tax RebatesOct 7, 2019
  • PharmAust receives ethics approval to begin Phase II TrialJul 15, 2019

Earlier from Neurizon Therapeutics

  • Phase IIb Canine Trial Identifies Therapeutic Window for MPLApr 26, 2021
  • PharmAust Receives $750k R&D Tax Incentive RefundApr 7, 2021
  • Leiden Testing Indicates MPL SARS-CoV-2 Antiviral ActivityApr 6, 2021
  • Update on Phase IIb Clinical Trial of Monepantel in Pet DogsMar 29, 2021
  • Licensing Agreement to Develop Waste to Fuels TechnologyMar 22, 2021

Later from Neurizon Therapeutics

  • Phase IIb Dog Trial Achieves Interim Clinical EndpointsJun 27, 2021
  • PharmAust and WEHI to Investigate HTLV-1 Viral InfectionsJul 11, 2021
  • Monepantel and monepantel sulfone COVID-19 anti-viral updateJul 26, 2021
  • Epichem Completes Build of OHD Benchtop Flow ReactorAug 2, 2021
  • Epichem Completes Final Loan RepaymentAug 30, 2021
All Neurizon Therapeutics news releases↗

Follow Neurizon Therapeutics into a list and get an email when it puts out news.

Follow Neurizon Therapeutics
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer